|
SMT202000196T1
(it)
|
2011-04-08 |
2020-05-08 |
Janssen Sciences Ireland Unlimited Co |
Derivati di pirimidina per il trattamento di infezioni virali
|
|
ES2690082T3
(es)
|
2011-11-09 |
2018-11-19 |
Janssen Sciences Ireland Uc |
Derivados de purina para el tratamiento de infecciones virales
|
|
EA033907B1
(ru)
*
|
2012-02-08 |
2019-12-09 |
Янссен Сайенсиз Айрленд Юси |
Производные пиперидино-пиримидина, фармацевтическая композиция и их применение
|
|
NZ702364A
(en)
|
2012-07-13 |
2016-09-30 |
Janssen Sciences Ireland Uc |
Macrocyclic purines for the treatment of viral infections
|
|
DK2906563T3
(en)
|
2012-10-10 |
2018-06-06 |
Janssen Sciences Ireland Uc |
PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES
|
|
UA118341C2
(uk)
|
2012-11-16 |
2019-01-10 |
ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі |
Гетероциклічні заміщені похідні 2-амінохіназоліну для лікування вірусних інфекцій
|
|
MY191389A
(en)
|
2013-02-21 |
2022-06-22 |
Janssen Sciences Ireland Uc |
2-aminopyrimidine derivatives for the treatment of viral infections
|
|
EP2978429B1
(en)
|
2013-03-29 |
2017-02-22 |
Janssen Sciences Ireland UC |
Macrocyclic deaza-purinones for the treatment of viral infections
|
|
WO2014187932A1
(en)
|
2013-05-24 |
2014-11-27 |
Janssen R&D Ireland |
Pyridone derivatives for the treatment of viral infections and further diseases
|
|
UA117590C2
(uk)
|
2013-06-27 |
2018-08-27 |
ЯНССЕН САЙЄНСЕЗ АЙРЛЕНД ЮСі |
ПОХІДНІ ПІРОЛО[3,2-d]ПІРИМІДИНУ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ІНФЕКЦІЙ ТА ІНШИХ ЗАХВОРЮВАНЬ
|
|
DK3404031T3
(da)
|
2013-07-30 |
2020-12-14 |
Janssen Sciences Ireland Unlimited Co |
Thieno[3,2-d]pyrimidinderivater til behandling af virusinfektioner
|
|
MD20170081A2
(ro)
|
2015-03-04 |
2018-03-31 |
Gilead Sciences, Inc. |
Compuşi 4,6-diamino-pirido[3,2-D]pirimidină modulatori ai receptorilor de tip Toll
|
|
JP2018525412A
(ja)
|
2015-08-26 |
2018-09-06 |
ギリアード サイエンシーズ， インコーポレイテッド |
重水素化トール様受容体調節因子
|
|
EP3349757A1
(en)
*
|
2015-09-15 |
2018-07-25 |
Gilead Sciences, Inc. |
Modulators of toll-like recptors for the treatment of hiv
|
|
SG10202108793TA
(en)
|
2015-12-15 |
2021-09-29 |
Gilead Sciences Inc |
Human immunodeficiency virus neutralizing antibodies
|
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
|
MA45088A
(fr)
|
2016-05-27 |
2019-04-10 |
Gilead Sciences Inc |
Méthodes pour traiter des infections par le virus de l'hépatite b au moyen d'inhibiteurs de ns5a, ns5b ou ns3
|
|
SG11201811448RA
(en)
*
|
2016-07-01 |
2019-01-30 |
Janssen Sciences Ireland Unlimited Co |
Dihydropyranopyrimidines for the treatment of viral infections
|
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
ES2826748T3
(es)
|
2016-09-02 |
2021-05-19 |
Gilead Sciences Inc |
Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
|
|
KR102268448B1
(ko)
|
2016-09-02 |
2021-06-22 |
길리애드 사이언시즈, 인코포레이티드 |
톨 유사 수용체 조정제 화합물
|
|
PL3510033T3
(pl)
*
|
2016-09-09 |
2022-03-07 |
Novartis Ag |
Związki i kompozycje jako inhibitory endosomalnych receptorów toll- podobnych
|
|
CA3037989A1
(en)
|
2016-09-29 |
2018-04-05 |
Janssen Sciences Ireland Unlimited Company |
Pyrimidine prodrugs for the treatment of viral infections and further diseases
|
|
KR20230010826A
(ko)
|
2016-10-14 |
2023-01-19 |
프리시젼 바이오사이언시스 인코포레이티드 |
B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
|
|
TWI820984B
(zh)
|
2017-01-31 |
2023-11-01 |
美商基利科學股份有限公司 |
替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
|
|
JOP20180008A1
(ar)
|
2017-02-02 |
2019-01-30 |
Gilead Sciences Inc |
مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
|
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
|
AR112412A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas de sal de colina de un inhibidor de la cápside del vih
|
|
AR112413A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas sólidas de un inhibidor de la cápside del vih
|
|
AU2018319538B9
(en)
|
2017-08-22 |
2021-05-27 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
|
TW201915000A
(zh)
*
|
2017-09-22 |
2019-04-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
稠合雜芳基衍生物、其製備方法及其在醫藥上的應用
|
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
|
AU2018385693A1
(en)
|
2017-12-15 |
2020-06-18 |
Silverback Therapeutics, Inc. |
Antibody construct-drug conjugate for the treatment of hepatitis
|
|
CN111511754B
(zh)
|
2017-12-20 |
2023-09-12 |
捷克共和国有机化学与生物化学研究所 |
活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
|
|
AU2018392213B2
(en)
|
2017-12-20 |
2021-03-04 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
|
|
KR102708681B1
(ko)
|
2018-02-13 |
2024-09-26 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
|
US10836746B2
(en)
|
2018-02-15 |
2020-11-17 |
Gilead Sciences, Inc. |
Therapeutic compounds
|
|
CN112055712B
(zh)
|
2018-02-16 |
2023-07-14 |
吉利德科学公司 |
用于制备可用于治疗逆转录病毒科病毒感染的治疗性化合物的方法和中间体
|
|
WO2019165374A1
(en)
|
2018-02-26 |
2019-08-29 |
Gilead Sciences, Inc. |
Substituted pyrrolizine compounds as hbv replication inhibitors
|
|
TWI772370B
(zh)
*
|
2018-02-26 |
2022-08-01 |
瑞士商諾華公司 |
作為胞內體類鐸（toll-like）受體抑制劑之化合物及組合物
|
|
TW201945003A
(zh)
|
2018-03-01 |
2019-12-01 |
愛爾蘭商健生科學愛爾蘭無限公司 |
２，４－二胺基喹唑啉衍生物及其醫學用途
|
|
US10870691B2
(en)
|
2018-04-05 |
2020-12-22 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis B virus protein X
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
CN112041311B
(zh)
|
2018-04-19 |
2023-10-03 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
|
TW202014193A
(zh)
|
2018-05-03 |
2020-04-16 |
捷克科學院有機化學與生物化學研究所 |
包含碳環核苷酸之2’3’－環二核苷酸
|
|
US12084460B2
(en)
|
2018-05-18 |
2024-09-10 |
Novartis Ag |
Crystalline forms of a TLR7/TLR8 inhibitor
|
|
ES3032898T3
(en)
|
2018-07-03 |
2025-07-28 |
Gilead Sciences Inc |
Antibodies that target hiv gp120 and methods of use
|
|
AU2019297362B2
(en)
|
2018-07-06 |
2022-05-26 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
|
KR102629921B1
(ko)
|
2018-07-06 |
2024-01-31 |
길리애드 사이언시즈, 인코포레이티드 |
치료 헤테로시클릭 화합물
|
|
SI3820572T1
(sl)
|
2018-07-13 |
2023-12-29 |
Gilead Sciences, Inc. |
Inhibitorji pd-1/pd-l1
|
|
CA3216031A1
(en)
|
2018-07-16 |
2020-01-23 |
Gilead Sciences, Inc. |
Capsid inhibitors for the treatment of hiv
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
US20200113912A1
(en)
|
2018-09-12 |
2020-04-16 |
Silverback Therapeutics, Inc. |
Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates
|
|
EP3860717A1
(en)
|
2018-10-03 |
2021-08-11 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
|
CA3117199C
(en)
|
2018-10-24 |
2024-03-19 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
TWI721624B
(zh)
|
2018-10-31 |
2021-03-11 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
|
ES2979163T3
(es)
|
2018-10-31 |
2024-09-24 |
Gilead Sciences Inc |
Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1
|
|
BR112021015577A8
(pt)
|
2019-02-08 |
2021-10-05 |
Research & Business Found Sungkyunkwan Univ |
Complexo-colesterol agonista do receptor toll-like 7/8, composição de nanopartícula, composição adjuvante, composição de vacina, composição para regular uma função imunológica, composição farmacêutica e uso do complexo
|
|
WO2020176510A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
|
WO2020176505A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
|
CN113574063B
(zh)
|
2019-03-07 |
2025-03-18 |
捷克共和国有机化学与生物化学研究所 |
3’3’-环二核苷酸及其前药
|
|
KR102707808B1
(ko)
|
2019-03-07 |
2024-09-19 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
|
|
US11766447B2
(en)
|
2019-03-07 |
2023-09-26 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
CR20210486A
(es)
|
2019-03-22 |
2021-12-07 |
Gilead Sciences Inc |
Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI762925B
(zh)
|
2019-05-21 |
2022-05-01 |
美商基利科學股份有限公司 |
鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
|
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
|
CA3140708A1
(en)
|
2019-06-18 |
2020-12-24 |
Helen Horton |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
|
US20220249685A1
(en)
|
2019-06-19 |
2022-08-11 |
Silverback Therapeutics, Inc. |
Anti-mesothelin antibodies and immunoconjugates thereof
|
|
PE20220231A1
(es)
|
2019-06-25 |
2022-02-07 |
Gilead Sciences Inc |
Proteinas de fusion flt3l-fc y metodos de uso
|
|
TWI879779B
(zh)
|
2019-06-28 |
2025-04-11 |
美商基利科學股份有限公司 |
類鐸受體調節劑化合物的製備方法
|
|
US11795210B2
(en)
|
2019-07-16 |
2023-10-24 |
Gilead Sciences, Inc. |
HIV vaccines and methods of making and using
|
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
EP4017476A1
(en)
|
2019-08-19 |
2022-06-29 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
KR20250040096A
(ko)
|
2019-09-30 |
2025-03-21 |
길리애드 사이언시즈, 인코포레이티드 |
Hbv 백신 및 hbv를 치료하는 방법
|
|
AU2020358726A1
(en)
|
2019-10-01 |
2022-04-07 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
|
CN114555123B
(zh)
|
2019-10-18 |
2024-04-02 |
四十七公司 |
用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
|
|
CA3153636A1
(en)
|
2019-10-31 |
2021-05-06 |
Forty Seven, Inc. |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
TWI854067B
(zh)
|
2019-11-26 |
2024-09-01 |
美商基利科學股份有限公司 |
預防hiv之蛋白殼抑制劑
|
|
EP4567109A2
(en)
|
2019-12-06 |
2025-06-11 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
|
EP4081305B1
(en)
|
2019-12-24 |
2024-09-18 |
Carna Biosciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
CN117964757A
(zh)
|
2020-02-14 |
2024-05-03 |
吉利德科学公司 |
与ccr8结合的抗体和融合蛋白及其用途
|
|
JP2023514727A
(ja)
|
2020-02-21 |
2023-04-07 |
シルバーバック セラピューティックス インコーポレイテッド |
ネクチン－４抗体コンジュゲートおよびその使用
|
|
WO2021177679A1
(ko)
|
2020-03-02 |
2021-09-10 |
성균관대학교산학협력단 |
병원균 외벽 성분 기반 생병원체 모방 나노 입자 및 그 제조 방법
|
|
EP4121437A1
(en)
|
2020-03-20 |
2023-01-25 |
Gilead Sciences, Inc. |
Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
|
|
MX2022013619A
(es)
|
2020-05-01 |
2022-11-16 |
Gilead Sciences Inc |
Compuestos de 2,4-dioxopirimidina que inhiben cd73.
|
|
TW202208355A
(zh)
|
2020-05-04 |
2022-03-01 |
美商安進公司 |
作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
|
|
CN116322696A
(zh)
|
2020-05-04 |
2023-06-23 |
安进公司 |
作为髓样细胞上表达的触发受体2激动剂的杂环化合物和使用方法
|
|
WO2021236944A1
(en)
|
2020-05-21 |
2021-11-25 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising bictegravir
|
|
EP4172157A1
(en)
|
2020-06-25 |
2023-05-03 |
Gilead Sciences, Inc. |
Capsid inhibitors for the treatment of hiv
|
|
CA3183993A1
(en)
|
2020-07-01 |
2022-01-06 |
Peter R. Baum |
Anti-asgr1 antibody conjugates and uses thereof
|
|
US20230355750A1
(en)
|
2020-08-04 |
2023-11-09 |
Progeneer Inc. |
Kinetically acting adjuvant ensemble
|
|
CN116322751A
(zh)
|
2020-08-04 |
2023-06-23 |
蛋白科技先锋 |
包含能够动力学控制的佐剂的mRNA疫苗
|
|
JP2023536954A
(ja)
|
2020-08-04 |
2023-08-30 |
プロジェニア インコーポレイテッド |
活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途
|
|
CA3186054A1
(en)
|
2020-08-07 |
2022-02-10 |
Daniel H. BYUN |
Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
|
|
TW202406932A
(zh)
|
2020-10-22 |
2024-02-16 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
WO2022103758A1
(en)
|
2020-11-11 |
2022-05-19 |
Gilead Sciences, Inc. |
METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
|
|
CN117279664A
(zh)
|
2021-04-10 |
2023-12-22 |
普方生物制药美国公司 |
Folr1结合剂、其偶联物及其使用方法
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
TW202308699A
(zh)
|
2021-04-23 |
2023-03-01 |
美商普方生物製藥美國公司 |
Ｃｄ７０結合劑、其結合物及其使用方法
|
|
US20240269142A1
(en)
|
2021-05-13 |
2024-08-15 |
Gilead Sciences, Inc. |
COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
|
|
TW202313094A
(zh)
|
2021-05-18 |
2023-04-01 |
美商基利科學股份有限公司 |
使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
|
|
IL309378A
(en)
|
2021-06-23 |
2024-02-01 |
Gilead Sciences Inc |
Diacylglyercol kinase modulating compounds
|
|
WO2022271650A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
EP4359411A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CN117355531A
(zh)
|
2021-06-23 |
2024-01-05 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
CA3234909A1
(en)
|
2021-10-28 |
2023-05-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
JP2024541979A
(ja)
|
2021-10-29 |
2024-11-13 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｃｄ７３化合物
|
|
WO2023102523A1
(en)
|
2021-12-03 |
2023-06-08 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv virus infection
|
|
FI4445900T3
(fi)
|
2021-12-03 |
2025-08-05 |
Gilead Sciences Inc |
Terapeuttisia yhdisteitä hiv-virusinfektiota varten
|
|
KR20240117588A
(ko)
|
2021-12-03 |
2024-08-01 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv 바이러스 감염 치료용 화합물
|
|
US20230203202A1
(en)
|
2021-12-08 |
2023-06-29 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
JP2024545185A
(ja)
*
|
2021-12-08 |
2024-12-05 |
シャンハイ ヴィソンファーマ カンパニー，リミテッド |
ＴＬＲ７／８作動剤としてのピリド［４，３－ｄ］ピリミジン系化合物
|
|
US20230220106A1
(en)
|
2021-12-08 |
2023-07-13 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
JP2024546851A
(ja)
|
2021-12-22 |
2024-12-26 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
|
|
WO2023122615A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
EP4464703A3
(en)
|
2022-03-17 |
2025-02-26 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
TW202446773A
(zh)
|
2022-04-06 |
2024-12-01 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
|
KR20250004824A
(ko)
|
2022-04-21 |
2025-01-08 |
길리애드 사이언시즈, 인코포레이티드 |
Kras g12d 조절 화합물
|
|
PE20250758A1
(es)
|
2022-07-01 |
2025-03-13 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
WO2024006982A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
|
|
WO2024015741A1
(en)
|
2022-07-12 |
2024-01-18 |
Gilead Sciences, Inc. |
Hiv immunogenic polypeptides and vaccines and uses thereof
|
|
US20240083984A1
(en)
|
2022-08-26 |
2024-03-14 |
Gilead Sciences, Inc. |
Dosing and scheduling regimen for broadly neutralizing antibodies
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
EP4598934A1
(en)
|
2022-10-04 |
2025-08-13 |
Gilead Sciences, Inc. |
4'-thionucleoside analogues and their pharmaceutical use
|
|
KR20250122479A
(ko)
|
2022-12-22 |
2025-08-13 |
길리애드 사이언시즈, 인코포레이티드 |
Prmt5 억제제 및 이의 용도
|
|
WO2024215754A1
(en)
|
2023-04-11 |
2024-10-17 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
US20240390349A1
(en)
|
2023-04-19 |
2024-11-28 |
Gilead Sciences, Inc. |
Dosing regimen of capsid inhibitor
|
|
WO2024220917A1
(en)
|
2023-04-21 |
2024-10-24 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
TW202504592A
(zh)
|
2023-05-31 |
2025-02-01 |
美商基利科學股份有限公司 |
固體形式
|
|
TW202448483A
(zh)
|
2023-05-31 |
2024-12-16 |
美商基利科學股份有限公司 |
用於ｈｉｖ之治療性化合物
|
|
WO2025006720A1
(en)
|
2023-06-30 |
2025-01-02 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
TW202519517A
(zh)
|
2023-07-26 |
2025-05-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
US20250066328A1
(en)
|
2023-07-26 |
2025-02-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025029247A1
(en)
|
2023-07-28 |
2025-02-06 |
Gilead Sciences, Inc. |
Weekly regimen of lenacapavir for the treatment and prevention of hiv
|
|
WO2025042394A1
(en)
|
2023-08-23 |
2025-02-27 |
Gilead Sciences, Inc. |
Dosing regimen of hiv capsid inhibitor
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025072406A1
(en)
|
2023-09-26 |
2025-04-03 |
Profoundbio Us Co. |
Ptk7 binding agents, conjugates thereof and methods of using the same
|
|
TW202515549A
(zh)
|
2023-10-11 |
2025-04-16 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
|
WO2025080850A1
(en)
|
2023-10-11 |
2025-04-17 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
|
US20250122219A1
(en)
|
2023-10-11 |
2025-04-17 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025137245A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Solid forms of hiv integrase inhibitors
|
|
WO2025149661A1
(en)
|
2024-01-10 |
2025-07-17 |
Genmab A/S |
Slitrk6 binding agents, conjugates thereof and methods of using the same
|